SHA raises cancer cover limit to Ksh500K
By Faith Lagat, October 9, 2025The Social Health Authority (SHA) has reaffirmed its commitment to strengthening cancer care and expanding oncology benefits, as outlined in a public notice issued on October 9, 2025.
Under the theme “SHA has raised the oncology package limit from Ksh400,000 to Ksh500,000, effective since April this year, marking a significant step toward enhancing access to quality and affordable healthcare for Kenyans.
This adjustment is part of a broader national health coverage program, transitioning from the National Health Insurance Fund (NHIF) to the Social Health Insurance coverage scheme.
Collaboration
The Authority acknowledged concerns raised by patients and caregivers regarding cancer care benefits and current tariffs, recognising the physical, emotional, and financial challenges faced by those affected. SHA’s core objective, as mandated by law, is to provide a framework for improved healthcare coverage and financial protection, ensuring Kenyans receive necessary care without undue hardship.
“The Authority acknowledges the concerns raised by patients and caregivers regarding cancer care benefits and current tariffs, recognising the physical, emotional, and financial challenges faced by those affected,” read the SHA notice in part dated October 9, 2025.
This commitment is further demonstrated through collaboration with the Kenya Network of Cancer Organizations (KENCO), whose memorandum has informed the development of benefits and tariffs packages.
“This commitment is further demonstrated through collaboration with the Kenya Network of Cancer Organisations (KENCO), whose memorandum has informed the development of benefits and tariff packages.”
Oncology package
To ensure comprehensive coverage, the recently gazetted Benefits Package and Tariffs Advisory Panel (BPTAP) is actively reviewing the oncology package, aiming to increase the limit for cancer treatment benefits.
The benefit package remains dynamic, regularly updated based on data, clinical evidence, and patient feedback to meet evolving health needs.
Strategic partnerships
SHA’s efforts extend beyond financial adjustments, including strategic partnerships with hospitals, professional associations, and pharmaceutical manufacturers to make treatment more affordable. A collaboration with ROCHE has lowered the price of Herceptin from Ksh 120,000 per 440mg to a more affordable option for eligible HER2-positive breast cancer patients.
This initiative aligns with the government’s objective to reduce oncology care costs and forms part of SHA’s broader health financing and system reform agenda. The Authority aims to make Kenya’s national health coverage more inclusive, efficient, and sustainable.
SHA remains open to feedback, committed to continuous improvement, and dedicated to ensuring no Kenyan is left behind in accessing lifesaving care, as stated by Chief Executive Officer Mercy Mwangangi.